Aaa Usa Inc Company Profile
What is the competitive landscape for AAA USA INC
AAA USA INC has one approved drug.
There are nine US patents protecting AAA USA INC drugs.
Drugs and US Patents for Aaa Usa Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aaa Usa Inc | LUTATHERA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aaa Usa Inc | LUTATHERA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | AP | RX | Yes | Yes | 11,904,027*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Aaa Usa Inc | LUTATHERA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | AP | RX | Yes | Yes | 12,151,003*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Aaa Usa Inc | LUTATHERA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aaa Usa Inc | LUTATHERA | lutetium lu-177 dotatate | SOLUTION;INTRAVENOUS | 208700-001 | Jan 26, 2018 | AP | RX | Yes | Yes | 12,161,732*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aaa Usa Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 4541379 | ⤷ Start Trial |
| South Korea | 102643582 | ⤷ Start Trial |
| Slovenia | 3826686 | ⤷ Start Trial |
| European Patent Office | 4541381 | ⤷ Start Trial |
| Lithuania | 4541380 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aaa Usa Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 4095130 | C04095130/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTID TETRAXETAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68684 24.02.2023 |
| 4095130 | 301281 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LUTETIUM (177-LU)-VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703, 20221212 |
| 4095130 | 23/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 (MITTEILUNG) 20221212 |
| 4095130 | LUC00352 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212 |
| 4095130 | CR 2024 00027 | Denmark | ⤷ Start Trial | PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

